Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
981-1000 of 3,900 trials

Radiprodil for Seizures in Tuberous Sclerosis and Focal Cortical Dysplasia

We are studying the safety and effects of radiprodil on seizures and behavior in patients with Tuberous Sclerosis Complex or Focal Cortical Dysplasia Type II. This research may help improve treatment options for these conditions.

Focal Cortical Dysplasia (FCD)Tuberous Sclerosis Complex (TSC)3-6 monthsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteNeurology

AUTO1 Treatment for Pediatric Blood Cancers

We are studying the safety and early effectiveness of AUTO1 in children with relapsed or refractory B cell acute lymphoblastic leukemia and aggressive mature B cell non-Hodgkin lymphoma. This trial aims to see how well the treatment works and how it can be safely administered.

B-cell Acute Lymphoblastic LeukemiaAggressive Mature B-cell Non-Hodgkin Lymphoma>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesHematologyOncology

Advanced Melanoma: RO7276389 and Cobimetinib Study

We are evaluating a new treatment for patients with advanced solid tumors or melanoma that have a specific genetic mutation. This study looks at the safety and early effects of the treatment alone and in combination with another drug.

Metastatic Melanoma>2 yearsSafety phase (I)Oncology

Melanoma Treatment: Pembrolizumab with New Agents

We are studying the safety and effectiveness of pembrolizumab alone or with new investigational treatments for people with melanoma. This research aims to find better options for managing this type of skin cancer.

Melanoma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Lung Cancer: V940 and Pembrolizumab Study

We are studying the effects of a new treatment combining V940 with pembrolizumab for patients with resectable stage II to IIIB lung cancer. The goal is to see if this combination improves disease-free survival compared to a placebo.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)16-20 visitsInvestigational MedicinesCost ReimbursementOncologyPulmonology

Suicidal Thoughts: Nitrous Oxide Treatment in Emergencies

We are studying whether inhaling a mix of nitrous oxide and oxygen can reduce suicidal thoughts in patients at emergency departments. The trial also looks at its effects on anxiety and depression symptoms over time.

Suicidal Thoughts≤3 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPsychiatry

Long-Term Safety Study of Ongoing Treatment with Study Drugs

We are providing continued access to a study drug for patients who are benefiting from it. The goal is to monitor its long-term safety as they continue treatment.

Metastatic Breast CancerMetastatic Non-Small Cell Lung CancerHER2 Positive Breast CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Plaque Psoriasis: Bimekizumab Study

We are exploring how bimekizumab affects gene expression in people with moderate to severe plaque psoriasis. The study also looks at the safety of this treatment for those with or without psoriatic arthritis.

Plaque PsoriasisPsoriatic Arthritis>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesDermatologyRheumatology

Major Depressive Disorder: NMRA-335140 Study

We are testing a new oral medication for adults with major depressive disorder to see if it helps improve their symptoms compared to a placebo. The study will measure changes in mood and daily functioning over six weeks.

Major Depressive Disorder≤3 monthsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

MB-CART2019.1 Therapy for Pediatric B-Cell Neoplasms

We are studying how safe and effective MB-CART2019.1 is for children and teens with relapsed or refractory B-cell cancers. This research aims to find better treatment options for those who haven't responded to other therapies.

Refractory or Recurrent B-cell Lymphoma1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncologyPediatrics

Uterine Leiomyosarcoma: Post-Operative Chemotherapy Study

We are investigating whether adding chemotherapy after surgery helps patients with high-risk localized uterine leiomyosarcoma avoid relapse. This study compares the new treatment approach to standard observation care.

Uterine LeiomyosarcomaEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Tourette Disorder: Serotonin and Impulsivity Study

We are investigating how serotonin receptors relate to impulsivity in adults with Tourette's syndrome. This study may help us understand brain activity and behavior during treatment.

Tourette Syndrome>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyPsychiatry

Bladder Cancer: Pembrolizumab and Enfortumab Combination

We are studying a combination of two medications for patients with first-line metastatic urothelial carcinoma. The aim is to evaluate their safety and effectiveness in treating this advanced cancer.

Bladder CancerSafety phase (I)Efficacy phase (II)Oncology

Advanced Urothelial Carcinoma: MK-2870 with Enfortumab Vedotin

We are studying a new treatment combining MK-2870 with Enfortumab Vedotin and Pembrolizumab for patients with advanced bladder cancer. The goal is to assess safety and how well it works compared to existing options.

Bladder Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Advanced Non-Small Cell Lung Cancer: JNJ-86974680 Study

We are exploring a new treatment for advanced non-small cell lung cancer using JNJ-86974680 alone and with other therapies. The goal is to see how well it works in combination with cetrelimab and radiotherapy.

Advanced Non-Small Cell Lung Cancer>2 yearsSafety phase (I)OncologyPulmonology

Immuno-OCT Imaging: Safety and Feasibility Study

We are exploring a new imaging technique using a tracer for patients undergoing endoscopy. The goal is to determine if this method is safe and effective for better visualization during procedures.

Barrett's EsophagusColon CarcinomaGastrointestinal DysplasiaSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementGastroenterologyOncology

Melanoma, NSCLC, and Cervical Cancer: ANV419 vs High-Dose IL-2

We are studying whether a new treatment (ANV419) is safer and improves outcomes compared to high-dose IL-2 for patients after tumor-infiltrating lymphocyte therapy. This trial also looks at quality of life and patient experiences.

Advanced Solid Tumors>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

IDOR-1134-2831 Vaccine: Healthy Participants Study

We are evaluating a new vaccine in healthy individuals to see how it is administered and its effects. This study aims to understand its safety and how the body responds to it.

Clostridium Difficile Infection>2 yearsSafety phase (I)Infectious Diseases

Chronic Lymphocytic Leukemia: New Triple Therapy Study

We are testing a new combination of medications for patients with high-risk chronic lymphocytic leukemia who haven't been treated before. The study aims to see if this new treatment can help keep the disease from progressing better than standard options.

High-Risk Hematological Patients>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

Chronic Kidney Disease: FINESSE Study on Albuminuria Reduction

We are researching how well finerenone and semaglutide can lower albuminuria in patients with chronic kidney disease. The goal is to find the most effective treatment for each individual and explore remote monitoring options.

Chronic Kidney Disease≤3 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteEndocrinologyNephrology